UNSPSC 51412002: Butalamine

This classification denotes a vasodilating agent with the molecular formula C18H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140T9JTG43, chemically known as 1,2-ethanediamine, n,n-dibutyl-n-(3-phenyl-1,2,4-oxadiazol-5-yl)- but generally known as butalamine, which bears US NIH Compound Identifier 30949. Butalamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05998MIG.

UNSPSC 51412002 Butalamine, a Commodity code, represents pharmaceutical supply contracts for emergency medications and broader generic drug programs serving state and local health agencies, fire departments, and cooperative purchasing consortia. State and local governments procure butalamine and related advanced life support medications through formal bid and RFP processes, typically bundling them with other injectable cardiovascular and respiratory agents for emergency medical services, hospital pharmacy programs, and state Medicaid or employee health plan formularies. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across dozens of jurisdictions. The mix reflects both direct procurement by individual cities and counties and indirect procurement through centralized cooperative vehicles that negotiate contracts on behalf of member agencies.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (due April 8, 2026) to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting models outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with a contract term of two years beginning July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation for reporting and onboarding failures.